Praziquantel Use Safe in Pregnancy - Says Study
Tuesday, 26 January 2016
Posted by: Psgh Editor
The results of the first clinical trial to investigate the efficacy and safety of praziquantel use in pregnant women infected with schistosomiasis have been published in the January issue of the Lancet Infectious Disease.
The study, a phase 2, randomized, double-blind, placebo-controlled trial was done in a village in Philippines endemic with schistosomiasis. The study enrolled pregnant women at 12-16 weeks of gestation infected with the organism.
Between the period of study (August, 2007 to December 2012) 370 pregnant women were enrolled and randomly assigned to received either placebo (n=184) or praziquantel (n=186).
Authors report that treatment with praziquantel did not have significant effect on birth weight. They further report that treatment was well tolerated with reactogenicity rates similar to those seen in non-pregnant participants. They were no significant differences in key safety outcomes including abortion, fetal death in utero, and congenital anomalies.
The findings of this study support an earlier recommendation made by the WHO to support the expansion of praziquantel use in pregnant women.